Patents by Inventor Dale A. Porter

Dale A. Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Service document generation using large language models
    Patent number: 11966845
    Abstract: A method for creating generated formatted data, that includes receiving, by a sequential data generator, raw data, where the raw data includes formation data at a drilling environment, processing the raw data to obtain generated recommendation data, where the generated recommendation data includes a proposed drilling location, and creating the generated formatted data, where the generated formatted data includes the generated recommendation data.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: April 23, 2024
    Assignee: Halliburton Energy Services, Inc.
    Inventors: Mateusz Michal Dyngosz, Charles Benjamin Broaddus, Aidan Porter, Dale E. Jamison
  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230121337
    Abstract: The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.
    Type: Application
    Filed: June 24, 2022
    Publication date: April 20, 2023
    Inventors: Louise Clare Kirman, Carl Eric Schwartz, Wojtek Michowski, Dale A. Porter, JR., Justin Ripper, John Feutrill
  • TEAD INHIBITORS AND USES THEREOF
    Publication number: 20230115350
    Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 29, 2022
    Publication date: April 13, 2023
    Inventors: Glen Robert Rennie, C. Eric Schwartz, Louise Kirman, Dale Porter, Ling Song
  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230109076
    Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 6, 2023
    Inventors: Louise Clare KIRMAN, Carl Eric SCHWARTZ, Wojtek MICHOWSKI, Dale A. PORTER, Justin RIPPER, John FEUTRILL, John Paul SHERRILL, Thomas P. BLAISDELL
  • TEAD INHIBITORS AND USES THEREOF
    Publication number: 20230098872
    Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 25, 2022
    Publication date: March 30, 2023
    Inventors: Glen Robert Rennie, C. Eric Schwartz, Louise Kirman, Dale Porter, Ling Song
  • TEAD INHIBITORS AND USES THEREOF
    Publication number: 20230053649
    Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 24, 2022
    Publication date: February 23, 2023
    Inventors: Glen Robert Rennie, C. Eric Schwartz, Dale Porter, Ling Song
  • Freeze Drying Methods
    Publication number: 20220125078
    Abstract: A freeze drying method including vacuuming freezing food, confirming operational status of at least one of a pressure sensor, a temperature sensor, a heating system, a cooling system, and/or a vacuum pump, and/or performing at least one of pre-frozen or not frozen status check, a chamber pre-freezing process, a vacuum leak check, a drying process, a final dry process, including any of such processes described in the specification.
    Type: Application
    Filed: June 7, 2021
    Publication date: April 28, 2022
    Inventors: Dale Porter, Daniel D. Neville, Rex C. Haddock
  • Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
    Patent number: 10765680
    Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 8, 2020
    Assignees: LES LABORATORIES SERVIER, NOVARTIS AG
    Inventors: Dale Porter, Ensar Halilovic, Maïa Chanrion, Ana Leticia Maragno, Olivier Geneste, Delphine Merino, James Whittle, François Vaillant, Jane Visvader, Geoffrey Lindeman, Guillaume Lessene, Elisabetta Marangoni
  • Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 10507201
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Diana Graus Porta, Carolina Haefliger, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Masato Murakami, Pierre Nimsgern, Michael Palmer, Dale Porter, Sebastien Ripoche, Can Wang, Youzhen Wang, Andreas Weiss, Jing Xiong, Xianglin Zhao
  • COMBINATION OF A MCL-1 INHIBITOR AND A TAXANE COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190336505
    Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Inventors: Dale PORTER, Ensar HALILOVIC, Maïa CHANRION, Ana Leticia MARAGNO, Olivier GENESTE, Delphine MERINO, James WHITTLE, François VAILLANT, Jane VISVADER, Geoffrey LINDEMAN, Guillaume LESSENE, Elisabetta MARANGONI
  • COMBINATION OF A BCL-2 INHIBITOR AND A MCL-1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190240225
    Abstract: A combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 8, 2019
    Applicants: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: Andrew WEI, Donia MOUJALLED, Giovanna POMILIO, Ana Leticia MARAGNO, Olivier GENESTE, Audrey CLAPERON, Heiko MAACKE, Ensar HALILOVIC, Dale PORTER, Erick MORRIS, Youzhen WANG, Sneha SANGHAVI, Prakash MISTRY
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190231760
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: February 28, 2019
    Publication date: August 1, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNOPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Pharmaceutical combinations
    Patent number: 10130629
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: November 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc, Lv Liao, Robert Mah, Dale Porter, Can Wang, Markus Wartmann, Jing Xiong, Xianglin Zhao
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20180185341
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: October 2, 2015
    Publication date: July 5, 2018
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Therapeutic Combination For The Treatment Of Cancer
    Publication number: 20170304313
    Abstract: This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or preventing a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Inventors: Dale Porter, Nafeeza Hafeez
  • Pharmaceutical combinations
    Patent number: 9446043
    Abstract: A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 20, 2016
    Assignee: Novartis AG
    Inventors: Dale Porter, Caroline Emery, Lujian Tan, Padmaja Yerramilli-Rao
  • Biomarkers for IAP inhibitor therapy
    Patent number: 9353419
    Abstract: A method of selecting a subject having cancer for treatment with an IAP inhibitor.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 31, 2016
    Assignee: Novartis AG
    Inventors: Dale Porter, John Scott Cameron, Caroline Emery, Douglas Robinson, Kavitha Venkatesan, Li Wang
  • Pharmaceutical Combinations
    Publication number: 20150306101
    Abstract: A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Application
    Filed: November 26, 2013
    Publication date: October 29, 2015
    Inventors: Dale PORTER, Caroline EMERY, Lujian TAN, Padmaja YERRAMILLI-RAO
  • BIOMARKERS FOR IAP INHIBITOR THERAPY
    Publication number: 20150105434
    Abstract: A method of selecting a subject having cancer for treatment with an IAP inhibitor.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 16, 2015
    Inventors: Dale Porter, John Scott Cameron, Caroline Emery, Douglas Robinson, Kavitha Venkatesan, Li Wang
  • BIOMARKERS FOR IAP INHIBITOR COMPOUNDS
    Publication number: 20120196793
    Abstract: A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels.
    Type: Application
    Filed: September 17, 2010
    Publication date: August 2, 2012
    Inventors: Brant G. Firestone, Kymberly Levine, Dale A. Porter, John Sullivan, Leigh Zawel